Source: Benzinga

Proteros: Proteros biostructures and Orion Pharma agree on a long-term multi-target collaboration including the assembly of a joint novel and unique HTS small-molecule screening library with the full chemistry support of Enamine

PreMarket Prep Press Releases Analyst Ratings News Options ETFs Real Time Feed Public RSS Feeds Submit News Tips Blog Embeddable Finance Widgets & Tools Benzinga Catalyst Affiliate Program Contributor Portal Licensing & Syndication Sponsored Content Advertise With Us Lead Generation & SEO About Us Careers In The News Events Contact Us Terms & Conditions Do Not Sell My Personal Data/Privacy Policy Disclaimer Service Status Sitemap

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
100-250
Torsten Neuefeind's photo - Co-Founder & CEO of Proteros

Co-Founder & CEO

Torsten Neuefeind

CEO Approval Rating

85/100

Read more